TC
OXFD

TFS Capital’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

TFS Capital’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,125
Closed -$219K – 837
2017
Q1 		$219K Buy
14,125
+2,337
+20% +$33.4K 0.07% 460
2016
Q4 		$176K Buy
+11,788
New +$165K 0.05% 554
2016
Q1 		– Sell
-10,651
Closed -$122K – 1142
2015
Q4 		$122K Buy
+10,651
New +$132K 0.01% 636
2014
Q4 		– Sell
-15,065
Closed -$230K – 1225
2014
Q3 		$230K Buy
15,065
+2,693
+22% +$41.2K 0.02% 829
2014
Q2 		$208K Buy
+12,372
New +$223K 0.02% 930

Other funds holding OXFD

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TFS Capital's OXFD Position: Q2 2017 in Review

TFS Capital sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2017, closing a stake of 14,125 shares — an estimated $219K sold.

TFS Capital first reported a position in OXFD in Q2 2014 and held it in 5 quarters. The position peaked at $230K in Q3 2014. 75 funds tracked by Wall St. Rank hold OXFD as of Q2 2017.

  • TFS Capital reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 14,125 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2017, an estimated $219K.
  • TFS Capital first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2014 and held it in 5 quarters.
  • TFS Capital's Oxford Immunotec Global PLC Ordinary Shares position peaked at $230K in Q3 2014.
  • 75 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.